Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$17.48
+2.9%
$19.76
$8.72
$27.41
$481.75M1.16233,149 shs41,289 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.39
+2.4%
$0.36
$0.33
$0.78
$424.50M0.38626,715 shs289,407 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-2.13%-3.96%-16.51%+12.07%-5.61%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
+4.08%+6.94%+10.98%+3.94%-49.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$17.48
+2.9%
$19.76
$8.72
$27.41
$481.75M1.16233,149 shs41,289 shs
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.39
+2.4%
$0.36
$0.33
$0.78
$424.50M0.38626,715 shs289,407 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-2.13%-3.96%-16.51%+12.07%-5.61%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
+4.08%+6.94%+10.98%+3.94%-49.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
2.83
Moderate Buy$29.0064.12% Upside
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CBIO and ELTP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
UpgradeSell (E)Sell (D-)
4/29/2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
DowngradeSell (E+)Sell (E)
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10.84M44.92N/AN/A$14.32 per share1.23
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M5.00$0.02 per share21.56$0.05 per share7.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$153.94M-$10.91N/AN/AN/AN/A-103.44%-88.19%7/30/2026 (Estimated)
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32M$0.0313.01N/AN/A30.98%47.93%25.81%6/29/2026 (Estimated)

Latest CBIO and ELTP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/29/2026Q1 2026
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$0.85-$0.70+$0.15-$0.70$0.36 million$1.04 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
13.78
13.78
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.05
7.34
5.44

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
4.00%
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5027.56 million26.46 millionNo Data
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.08 billion921.81 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$17.48 +0.49 (+2.88%)
As of 01:12 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.39 +0.01 (+2.36%)
As of 12:36 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.